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The Effect of p53 Status of Tumor Cells on Radiosensitivity 
of Irradiated Tumors With Carbon-Ion Beams Compared 
With γ-Rays or Reactor Neutron Beams
Shin-ichiro Masunagaa, f, Akiko Uzawab, Ryoichi Hirayamab, Yoshitaka Matsumotoc, Yoshinori Sakuraid, 
Hiroki Tanakad, Keizo Tanoa, Yu Sanadaa, Minoru Suzukie, Akira Maruhashid, Koji Onoe
Abstract
Background: The aim of the study was to clarify the effect of p53 
status of tumor cells on radiosensitivity of solid tumors following ac-
celerated carbon-ion beam irradiation compared with γ-rays or reac-
tor neutron beams, referring to the response of intratumor quiescent 
(Q) cells.
Methods: Human head and neck squamous cell carcinoma cells trans-
fected with mutant TP53 (SAS/mp53) or with neo vector (SAS/neo) 
were injected subcutaneously into hind legs of nude mice. Tumor-
bearing mice received 5-bromo-2’-deoxyuridine (BrdU) continuously 
to label all intratumor proliferating (P) cells. They received γ-rays or 
accelerated carbon-ion beams at a high or reduced dose-rate. Other 
tumor-bearing mice received reactor thermal or epithermal neutrons 
at a reduced dose-rate. Immediately or 9 hours after the high dose-
rate irradiation (HDRI), or immediately after the reduced dose-rate 
irradiation (RDRI), the tumor cells were isolated and incubated with 
a cytokinesis blocker, and the micronucleus (MN) frequency in cells 
without BrdU labeling (Q cells) was determined using immunofluo-
rescence staining for BrdU.
Results: The difference in radiosensitivity between the total (P + Q) 
and Q cells after γ-ray irradiation was markedly reduced with reactor 
neutron beams or carbon-ion beams, especially with a higher linear 
energy transfer (LET) value. Following γ-ray irradiation, SAS/neo 
tumor cells, especially intratumor Q cells, showed a marked reduc-
tion in sensitivity due to the recovery from radiation-induced dam-
age, compared with the total or Q cells within SAS/mp53 tumors that 
showed little repair capacity. In both total and Q cells within both 
SAS/neo and SAS/mp53 tumors, carbon-ion beam irradiation, es-
pecially with a higher LET, showed little recovery capacity through 
leaving an interval between HDRI and the assay or decreasing the 
dose-rate. The recovery from radiation-induced damage after γ-ray 
irradiation was a p53-dependent event, but little recovery was found 
after carbon-ion beam irradiation. With RDRI, the radiosensitivity 
to reactor thermal and epithermal neutron beams was slightly higher 
than that to carbon-ion beams.
Conclusion: For tumor control, including intratumor Q-cell control, 
accelerated carbon-ion beams, especially with a higher LET, and re-
actor thermal and epithermal neutron beams were very useful for sup-
pressing the recovery from radiation-induced damage irrespective of 
p53 status of tumor cells.
Keywords: p53 status; Quiescent cell; Carbon-ion beams; Reactor 
neutron beams; γ-rays
Introduction
It was shown that the p53 tumor suppressor gene serves a criti-
cal role in maintaining genomic stability during the cell cycle 
checkpoint in G1 and G2/M transition, and as an effector of 
DNA repair and apoptosis [1, 2]. Wild-type p53 is needed to 
activate apoptosis in sensitive cells in response to DNA dam-
age [1, 2]. These actions of p53 are potentially critical in de-
termining the effectiveness of ionizing radiation and/or chem-
otherapeutic agents. p53 is mutated in a majority of human 
solid tumors and plays a central role in the cellular response 
to DNA-damaging treatments like ionizing radiation, chemo-
therapy or hypoxic stress [3]. Hypoxic stress also induces p53 
protein accumulation and p53-dependent apoptosis, but does 
not induce p53-dependent cell cycle arrest [3]. Loss of p53 
function may result in resistance to DNA-damaging agents, in-
cluding ionizing radiation and hypoxic stress [1, 3]. Actually, 
mutations in the p53 tumor suppressor gene have an impact 
on the clinical course of several human cancers: patients with 
cancers harboring p53 mutations often have a worse prognosis 
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than those with tumors harboring wild-type p53 [1, 3]. Thus, 
the genetic and functional status of the p53 gene is an impor-
tant factor in guiding therapeutic strategies for cancer patients.
Meanwhile, charged particle beams, including protons and 
heavy ions, can offer improved dose conformation to the target 
volume compared with photon or neutron radiotherapy, with 
better sparing of normal tissue structures close to the target [4]. 
In addition, ion beams heavier than helium exhibit a strong in-
crease in linear energy transfer (LET) in the Bragg peak com-
pared with the entrance region [4]. These physical properties 
are very advantageous in radiotherapy.
Also, high LET radiation, including neutrons, is more ef-
fective [5] than low LET X- or g-radiation at inducing biologic 
damage. High LET radiation results in a greater relative bio-
logic effectiveness (RBE) value for cell killing, a reduced oxy-
gen effect [6], and a reduced dependence on the cell cycle [7, 
8], making it potentially superior to low LET radiation in the 
treatment of malignant tumors. The reactor thermal and epith-
ermal neutron beams available at our institute have also been 
shown to have a significantly greater RBE value than γ-rays 
in irradiated tumor cells in vivo [9]. Owing to the selective 
physical dose distribution and enhanced biologic damage in 
target tumors, particle radiotherapy with protons or heavy ions 
has gained increasing interest worldwide, and many clinical 
centers are considering introducing radiotherapy with charged 
particles. However, almost all these biologic advantages of 
charged particle beams were determined only from the effects 
on tumor cell populations as a whole using in vitro cell cultures 
or in vivo solid tumors [4].
Many cells in solid tumors are quiescent (Q) in situ but 
are still clonogenic [10]. The Q tumor cell population has been 
thought to be more resistant to low LET radiation because of 
its much larger hypoxic fraction and greater potentially lethal 
damage repair (PLDR) capacity than the proliferating (P) tu-
mor cell population, mainly determined by the characteristics 
of plateau-phase-cultured cells in vitro [10]. To date, using our 
method for selectively detecting the response of intratumor Q 
cell populations in vivo, we have already shown that almost all 
these characteristics can also be applied to Q state cells within 
solid tumors in vivo [11].
In this study, we examined the characteristics of radio-
sensitivity in the total (P + Q) and Q cell populations in solid 
tumors irradiated with 290 MeV/u accelerated carbon-ion 
beams at varying LET values in a 6-cm spread-out Bragg peak 
(SOBP) installed at the National Institute of Radiological Sci-
ences (Chiba, Japan) compared with irradiation with 60C γ-rays 
and reactor thermal and epithermal neutron beams at our insti-
tute with our method for selectively detecting the response of 
Q cells within solid tumors [11], using two different tumor cell 
lines with identical genetic backgrounds except for p53 status.
Materials and Methods
Cells, tumors and mice
The human head and neck squamous cell carcinoma cell 
line SAS (JCRB, Tokyo) was cultured at 37 °C in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 20 mM 
2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid 
(HEPES) and 12.5% fetal bovine serum in a conventional hu-
midified 5% CO2 incubator. SAS cells show the phenotype of 
wild-type p53 in radiation- and heat-induced signal transduc-
tion [12, 13]. Plasmid pC53-248, which contains an mp53 gene 
(codon 248, from Arg to Trp) producing a dominant negative 
mp53 protein, and plasmid pCMV-Neo-Bam, which contains a 
neo-resistance marker, were provided by B. Vogelstein (Johns 
Hopkins Oncology Center, Baltimore, MD). These plasmids 
were linearized with HindIII. Confluent SAS cells, approxi-
mately 2 × 106 cells in a 75-cm2 flask, were trypsinized, and 
the resulting cell suspension in phosphate-buffered saline 
(PBS) (1 mL) was transferred into an electroporation chamber. 
Cells were supplemented with linearized DNA (10 μg/10 μL 
of pC53-248 or pCMV-Neo-Bam), and electroporated three 
times at 600 V. After standing for 30 min at room temperature, 
cells were plated onto dishes 10 cm in diameter in DMEM and 
incubated at 37 °C. Forty-eight hours later, cells were treated 
with G418 (geneticin, 200 μg/mL, Sigma Chemical Co., St. 
Louis, MO), an agent for selection of transfected clones, and 
then incubated at 37 °C for 14 days to allow colony formation. 
Colonies resistant to G418 were isolated with cloning cylin-
ders. Through these manipulations, two stable transfectants 
SAS/mp53 and SAS/neo were established. SAS/neo cells have 
a functionally wild-type p53 protein, and SAS/ mp53 cells ex-
press a dominant-negative p53 protein. The procedure used for 
transfection is described in detail elsewhere [12, 13].
Cells were collected from exponentially growing cultures, 
and approximately 5.0 × 105 cells were inoculated subcutane-
ously into both hind legs of 6- to 7-week-old syngeneic female 
Balb/cA nude mice. Three weeks after inoculation, a tumor 
with a diameter of approximately 7 mm could be observed at 
each implanted site, whichever stable transfectant was used.
Meanwhile, in locally advanced or recurrent head and 
neck tumors, especially which are refractory to conventional 
cancer therapy including radiation therapy using low LET ra-
diation X-rays, p53 status of the tumor cells is often mutated 
and the tumors often show hypoxic tendency rather than fresh 
and non-treated virgin tumors [14, 15]. In the treatment of 
inoperable refractory advanced and recurrent head and neck 
tumors, neutron capture therapy (NCT) has been performed 
since early 2001 as a clinical study at our research reactor insti-
tute [16, 17]. Since October 2012, NCT for inoperable refrac-
tory locally advanced and recurrent head and neck tumors has 
been conducted as a clinical trial.
Labeling with 5-bromo-2’-deoxyuridine (BrdU)
Two weeks after tumor cell inoculation, mini-osmotic pumps 
(Durect Corporation, Cupertino, CA) containing BrdU dis-
solved in physiological saline (250 mg/mL) were implanted 
subcutaneously to label all P cells for 7 days. Administration 
of BrdU did not change the tumor growth rate. The tumors 
were approximately 7 mm in diameter on treatment. The labe-
ling index (LI) after continuous labeling with BrdU was 48.4% 
(41.7-55.1%) (mean (95% confidence limit)) and 43.2% (37.0-
49.4%) for SAS/neo and SAS/mp53 tumor cells, respectively, 
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and reached a plateau level at these stages. Therefore, in this 
study, we regarded tumor cells not incorporating BrdU after 
continuous labeling as Q cells.
Irradiation
After labeling with BrdU, the tumor-bearing mice underwent 
accelerated carbon-ion beam irradiation, γ-ray irradiation, or 
reactor thermal or epithermal neutron beam irradiation. The 
irradiation was performed with the tumor-bearing mice held 
in a specially designed device made of acrylic resin with the 
tail or both arms and legs firmly fixed with an adhesive tape, 
without anesthesia.
Carbon-12 ions were accelerated up to 290 MeV/u by the 
synchrotron of the Heavy Ion Medical Accelerator installed at 
the National Institute of Radiological Sciences, Chiba, Japan. 
The accelerator was originally set up mainly for radiotherapy 
for malignant solid tumors refractory to conventional cancer 
therapy [18]. The radiation dose-rate was regulated through 
the beam attenuation system, and irradiation was conducted 
using horizontal carbon beams with a dose rate of 1.0 Gy/min 
and 0.037 Gy/min for high dose-rate irradiation (HDRI) and 
reduced dose-rate irradiation (RDRI), respectively. The LET 
of the 290 MeV/u carbon beam with the 6-cm SOBP ranged 
from 14 keV/mm to > 200 keV/mm, depending on the depth. A 
desired LET beam was obtained by selecting the depth along 
the beam path using a Lucite range shifter. Carbon beams with 
18 and 50 keV/mm LET were obtained at the middle of the 
plateau and at the middle of the SOBP. A desired irradiation 
field was obtained by the simultaneous use of an iron collima-
tor and a brass collimator [19].
γ-Ray irradiation was performed with a 60Co γ-ray irra-
diator available at our institute at a dose-rate of 2.5 Gy/min, 
such as conventionally used for HDRI. RDRI was performed 
at a dose-rate of 0.039 Gy/min by maintaining an appropriate 
distance between the 60Co radiation source and the irradiated 
tumor-bearing mouse fixed within the specially constructed 
device.
Thermal and epithermal neutron irradiations were per-
formed using a reactor neutron beam from our reactor with a 
cadmium ratio of 160 and 1.0, respectively. The neutron flu-
ence was measured from the radioactivation of gold foil at the 
front and back of the irradiated tumors. Because the tumors 
were small and located just beneath the surface, the neutron 
fluence was assumed to decrease linearly from the front to the 
back of the tumors. Thus, we used the average neutron fluence 
determined from the values measured at the front and back. 
Contaminating γ-ray, including secondary γ-ray, doses were 
measured with a thermoluminescence dosimeter powder at the 
back of the tumors. For the estimation of neutron energy spec-
tra, eight kinds of activation foils and 14 kinds of nuclear reac-
tions were used. The absorbed dose was calculated using the 
flux/dose conversion factor [20]. The tumors were assumed to 
contain, in weight percentages, 10.7%, 12.1%, 2%, 71.4%, and 
3.8% of hydrogen, carbon, nitrogen, oxygen, and other chemi-
cal elements, respectively [20].
The tumor-bearing mice fixed within the specially con-
structed devices were irradiated at a maximum neutron flux 
just in front of the neutron-radiating bismuth layer of the heavy 
water facility at our reactor. The neutron flux and Kerma rate 
of the thermal neutron beams were 2.0 × 109 n/cm2/s and 98.5 
cGy/h for the thermal neutron range (< 0.6 eV), 1.7 × 107 n/
cm2/s and 0.38 cGy/h for the epithermal neutron range (0.6 
- 10 keV), and 3.4 × 106 n/cm2/s and 22.9 cGy/h for the fast 
neutron range (> 10 keV), respectively. The contaminating 
γ-ray dose-rate was 100 cGy/h. All together, the irradiation 
dose-rate was 0.037 Gy/min. The corresponding values for the 
epithermal beams were 3.0 × 107 n/cm2/s and 0.24 cGy/h for 
the thermal neutron range, 7.3 × 108 n/cm2/s and 22.4 cGy/h 
for the epithermal neutron range, and 4.7 × 107 n/cm2/s and 
163 cGy/h for the fast neutron range. The contaminating γ-ray 
dose-rate was 62.0 cGy/h. As a whole, the irradiation dose-
rate was 0.041 Gy/min [20]. Taking the values of the dose-
rate used for accelerated carbon-ion beam and γ-ray irradiation 
into account, each neutron beam irradiation was thought to be 
equivalent to the RDRI. However, each dose-rate at each reac-
tor neutron beam irradiation was the maximal value available 
at our reactor [20].
According to the International Commission on Radiation 
Units and Measurements Report 58 concerning dosimetry in 
intracavitary brachytherapy for uterine cancer, high, middle, 
and low dose-rate irradiation is defined as > 0.2 Gy/min (12 
Gy/h), 0.033 - 0.2 Gy/min (2 - 12 Gy/h), and < 0.033 Gy/min 
(2 Gy/h), respectively [21]. Thus, the HDRI and RDRI used in 
the present study fit with the high dose-rate and middle dose-
rate irradiation, respectively.
Each irradiation group also included mice that had not 
been pretreated with BrdU. The tumors were then excised im-
mediately or 12 h after irradiation.
Immunofluorescence staining of BrdU-labeled cells and 
observation of micronucleus (MN) formation
The tumors were excised from mice given BrdU, minced, 
and trypsinized (0.05% trypsin and 0.02% ethylenediamine-
tetraacetic acid (EDTA) in PBS at 37 °C for 15 min). The tu-
mor cell suspensions were incubated for 48 h in tissue culture 
dishes containing complete medium and 1.0 μg/mL of cytoch-
alasin-B to inhibit cytokinesis while allowing nuclear division, 
and the cultures were then trypsinized and cell suspensions 
were fixed. After the centrifugation of fixed cell suspensions, 
the cell pellet was resuspended with cold Carnoy’s fixative. 
The suspension was then placed on a glass microscope slide 
and the sample was dried at room temperature. The slides were 
treated with 2 M hydrochloric acid for 45 min at room tem-
perature to dissociate the histones and partially denature the 
DNA. The slides were then immersed in borax-borate buffer 
(pH 8.5) to neutralize the acid. BrdU-labeled tumor cells were 
detected by indirect immunofluorescence staining using mono-
clonal anti-BrdU antibody (Becton Dickinson, San Jose, CA) 
and fluorescein isothiocyanate (FITC)-conjugated antimouse 
immunoglobulin G (whole molecule) antibody (Sigma, St. 
Louis, MO). To observe double staining of tumor cells with 
green-emitting FITC and red-emitting propidium iodide (PI), 
cells on the slides were treated with PI and monitored under a 
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fluorescence microscope.
The MN frequency in BrdU-unlabeled cells (Q cells at ir-
radiation) could be examined by counting the micronuclei in 
the binuclear cells that showed only red fluorescence. The MN 
frequency was defined as the ratio of the number of micronu-
clei in the binuclear cells to the total number of binuclear cells 
observed [9, 11].
The ratios obtained in tumors not pretreated with BrdU 
indicated the MN frequency at all phases in the total (P + Q) 
tumor cell populations. More than 300 tumor cells and binu-
clear cells were counted to determine the apoptosis frequency 
and the MN frequency, respectively.
Needless to say, the induction of an MN requires division 
of the cell nucleus [22]. The duration of incubation with cy-
tochalasin-B allowed Q cells to be recruited into the cell cycle. 
Thus, the optimal incubation period was determined so that 
the maximum rate of binuclear tumor cells could be observed. 
The frequencies of MN for BrdU-labeled cells were modified 
because the radiosensitization effect of the incorporated BrdU 
could potentially influence the frequencies in BrdU-labeled 
cells. Thus, the correct frequencies of BrdU-labeled cells 
without the BrdU effect are not able to be determined. During 
continuous labeling with BrdU, the shift of cells from P to Q 
population could result in labeled Q cells. These cells were ex-
cluded when we scored micronuclei in binuclear cells in tumor 
cells showing only red fluorescence by PI for DNA staining, 
because these cells were stained with FITC.
Cell survival assay
The cell survival assay was also performed in mice given no 
BrdU using an in vivo-in vitro assay method. Tumors were dis-
aggregated by stirring for 20 min at 37 °C in PBS containing 
0.05% trypsin and 0.02% EDTA. The cell yield was 1.5 (1.2 
- 1.8) × 107/g and 3.4 (2.6 - 4.2) × 106/g for SAS/neo and SAS/
mp53 tumors, respectively.
To confirm the stability of transfectants SAS/neo and 
SAS/mp53, part of the tumor cell suspensions obtained after 
irradiation and tumor cells from part of the colonies grown 
through the in vivo-in vitro assay method were subjected to 
western blotting analysis for p53 and Bax proteins as described 
by Ota et al [23]. Not only the level, but also the function of 
p53 protein could be detected because the bax gene is a target 
of the p53 gene. As a result, it was confirmed that the p53 sta-
tus of each transfectant was not changed by these experimental 
procedures. Three mice were used to assess each set of condi-
tions and each experiment was repeated three times. To exam-
ine the differences between pairs of values, Student’s t-test was 
used when variances of the two groups could be assumed to be 
Table 1.  Plating Efficiency and Micronucleus Frequency at 0 Gy
Total tumor cells Quiescent cells
SAS/neo
  Plating efficiency (%) 45.5 ± 8.9a
  Micronucleus frequency 0.038 ± 0.006 0.056 ± 0.007
SAS/mp53
  Plating efficiency (%) 23.5 ± 4.1
  Micronucleus frequency 0.072 ± 0.008 0.111 ± 0.010
aMean ± standard error (n = 6).
Figure 1. Surviving fractions and net micronucleus frequencies following γ-ray irradiation. The clonogenic cell survival curves 
for total tumor cell populations and the net micronucleus frequencies for total and quiescent cell populations immediately and 
9 h after γ-ray irradiation with high dose-rate irradiation (HDRI) and immediately after γ-ray irradiation with reduced dose-rate 
irradiation (RDRI) are shown in (a) and (b), respectively. The left and right panels show SAS/neo and SAS/mp53 tumor cells, 
respectively. Bars represent standard errors (n = 6). 
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equal, otherwise the Welch t-test was used. P values were from 
two-sided tests.
Results
Table 1 shows the plating efficiencies for the total tumor cell 
population and the MN frequencies without radiation for the 
total and Q cell populations in each tumor. Overall, SAS/mp53 
tumor cells showed significantly lower plating efficiency in the 
total cell populations and significantly higher MN frequencies 
in both the total and Q cell populations (P < 0.05) than SAS/
neo tumor cells. Further, Q cells showed significantly higher 
MN frequencies than the total cell population under each set of 
conditions in each tumor (P < 0.05).
The clonogenic cell survival curves for total tumor cell 
populations and the net MN frequencies of total and Q cell 
populations after γ-ray irradiation with HDRI or RDRI are 
shown in Figure 1a and b, respectively. For baseline correction, 
we used the net MN frequency to exclude the MN frequency in 
non-irradiated control tumors. The net MN frequency was the 
MN frequency in the irradiated tumors minus that in the non-
irradiated tumors. On the whole, SAS/mp53 tumor cells and Q 
tumor cells were more radioresistant than SAS/neo tumor cells 
and the total tumor cell population, respectively. The increase 
in the surviving fraction (SF) with the 9 h delayed assay, that 
is, PLDR, and the increase in the SF after RDRI were observed 
more clearly in SAS/neo than in SAS/mp53. The decrease in 
the net MN frequency with the 9 h delayed assay and the de-
crease in the net MN frequency after RDRI were more obvious 
Figure 2. Surviving fractions and net micronucleus frequencies following accelerated carbon-ion beam (18 MeV/μm) irradiation. 
The clonogenic cell survival curves for total tumor cell populations and the net micronucleus frequencies for total and quiescent 
cell populations immediately and 9 h after irradiation using accelerated carbon-ion beams with a linear energy transfer of 18 MeV/
μm with high dose-rate irradiation (HDRI) and immediately after irradiation with reduced dose-rate irradiation (RDRI) are shown 
in (a) and (b), respectively. The left and right panels show SAS/neo and SAS/mp53 tumor cells, respectively. Bars represent 
standard errors (n = 6). 
Figure 3. Surviving fractions and net micronucleus frequencies following accelerated carbon-ion beam (50 MeV/μm) irradiation. 
The clonogenic cell survival curves for total tumor cell populations and the net micronucleus frequencies for total and quiescent 
cell populations immediately and 9 h after irradiation using accelerated carbon-ion beams with a linear energy transfer of 50 MeV/
μm with high dose-rate irradiation (HDRI) and immediately after irradiation with reduced dose-rate irradiation (RDRI) are shown 
in (a) and (b), respectively. In addition, the cell survival curves for total cells and the net micronucleus frequencies for total and 
quiescent cells immediately after irradiation using reactor thermal and epithermal neutron beams are also shown in (a) and (b), 
respectively. The left and right panels show SAS/neo and SAS/mp53 tumor cells, respectively. Bars represent standard errors 
(n = 6). 
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in SAS/neo and Q cells than in SAS/mp53 and the total cell 
population, respectively.
The clonogenic cell survival curves for total tumor cell 
populations and the net MN frequencies of total and Q cell 
populations following HDRI or RDRI using carbon-ion beams 
with 18 keV/μm LET are shown in Figure 2a and b, respec-
tively. The clonogenic cell survival curves for total tumor cell 
populations and the net MN frequencies of total and Q cell 
populations following HDRI or RDRI using carbon-ion beams 
with 50 keV/μm LET are also shown in Figure 3a and b, re-
spectively, including the data for immediately after RDRI with 
reactor thermal or epithermal neutron beams. On the whole, 
in terms of the SF, the difference in sensitivity between SAS/
neo and SAS/mp53 tumors was reduced through employing 
carbon-ion beams instead of γ-rays. The difference in sensitiv-
ity between Q and total tumor populations was also reduced 
through employing carbon-ion beams instead of γ-rays in 
terms of the MN frequency. The increase in the SF with the 
9 h delayed assay and after RDRI were inhibited through us-
ing carbon-ion beam irradiation. The decrease in the net MN 
frequency with the 9 h delayed assay and after RDRI were also 
repressed with carbon-ion beam irradiation.
To evaluate the recovery capacity from the damage in-
duced by HDRI or during RDRI in total and Q cell populations 
within these two tumors, dose modifying factors were calcu-
lated in both cell populations at various endpoints using the 
Table 2.  Dose-Modifying Factors Due to a Delayed Assay or Reduced Irradiation Dose-Ratea
Employed Radiation beams High dose-rate 9 h after Reduced dose-rate
SAS/neo
  Surviving fraction = 0.03
    Total cells
      γ-rays 1.3 ± 0.1b 1.4 ± 0.1
      Carbon beams (18 keV/μm) 1.2 ± 0.1 1.15 ± 0.1
      Carbon beams (50 keV/μm) 1.15 ± 0.1 1.1 ± 0.1
  Net micronucleus frequency = 0.1
    Total cells
      γ-rays 1.35 ± 0.1 1.45 ± 0.1
      Carbon beams (18 keV/μm) 1.15 ± 0.1 1.2 ± 0.1
      Carbon beams (50 keV/μm) 1.15 ± 0.1 1.15 ± 0.1
    Quiescent cells
      γ-rays 1.45 ± 0.15 1.55 ± 0.15
      Carbon beams (18 keV/μm) 1.3 ± 0.1 1.35 ± 0.1
      Carbon beams (50 keV/μm) 1.25 ± 0.15 1.3 ± 0.1
SAS/mp53
  Surviving fraction = 0.03
    Total cells
      γ-rays 1.05 ± 0.1b 1.1 ± 0.1
      Carbon beams (18 keV/μm) 1.05 ± 0.1 1.05 ± 0.1
      Carbon beams (50 keV/μm) 1.05 ± 0.1 1.05 ± 0.1
  Net micronucleus frequency = 0.1
    Total cells
      γ-rays 1.05 ± 0.1 1.1 ± 0.1
      Carbon beams (18 keV/μm) 1.05 ± 0.1 1.1 ± 0.1
      Carbon beams (50 keV/μm) 1.05 ± 0.1 1.05 ± 0.1
    Quiescent cells
      γ-rays 1.05 ± 0.1 1.1 ± 0.1
      Carbon beams (18 keV/μm) 1.05 ± 0.1 1.1 ± 0.1
      Carbon beams (50 keV/μm) 1.05 ± 0.1 1.1 ± 0.1
aThe ratio of the dose of radiation necessary to obtain each endpoint with a delayed assay or reduced dose-rate ir-
radiation to that needed to obtain each endpoint with an assay immediately after high dose-rate irradiation. bMean ± 
standard error (n = 6).
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data given in Figures 1-3 (Table 2). Overall, regardless of the 
cell populations, SAS/mp53 tumor cells showed little recovery 
capacity under any irradiation conditions. In SAS/neo tumor 
cells, whether 9 h after HDRI or after RDRI, the recovery ca-
pacities following γ-ray irradiation were significantly greater 
in Q cell populations than total cell populations (P < 0.05). 
Carbon-ion beam irradiation inhibited the recovery from the 
damage induced by HDRI and through RDRI with a more re-
markable inhibition in Q cells than in the total cell population, 
especially when carbon-ion beams with a higher LET were 
employed.
To compare the cell survival curve between these two tu-
mor cells, we calculated the dose ratios for SAS/mp53 tumor 
cells relative to SAS/neo tumor cells (Table 3). The factors 
were calculated by comparing the radiation doses to obtain SF 
= 0.03 in SAS/mp53 tumor cells with the doses required in 
SAS/neo tumor cells. Following γ-ray irradiation, the values 
were decreased by the delayed assay after HDRI or a decreas-
ing irradiation dose-rate because of the apparent recovery from 
radiation-induced damage in SAS/neo tumor cells, compared 
with SAS/mp53 tumor cells that showed little recovery capac-
ity. However, following carbon-ion or reactor thermal or epi-
thermal neutron beam irradiation, the values were kept almost 
constant mainly because of efficiently suppressing recovery 
from radiation-induced damage in SAS/neo tumor cells.
To evaluate the RBE of the carbon-ion beams with vari-
ous LET values and the reactor thermal and epithermal neu-
tron beams in the total and Q cell populations compared with 
γ-rays, we used the data given in Figures 1-3 (Table 4). Over-
all, for all irradiation conditions, the values of RBE for Q cells 
were significantly larger than those for the total cell popula-
tion (P < 0.05). For carbon-ion beams, in the total and Q cell 
populations, the RBE values for immediately after RDRI were 
significantly larger than those for immediately after HDRI (P 
< 0.05). Those for 9 h after HDRI were also larger than those 
for immediately after HDRI, although not as large as those 
for immediately after RDRI. As the LET value increased (i.e., 
as the irradiated point became deeper within the SOBP of the 
carbon-ion beam), the values of RBE in the total and Q cells 
increased. The RBE values for the reactor thermal neutron 
beams were further higher than those for the carbon-ion beams 
with the higher LET value (50 keV/μm), and those for epither-
mal beams were greater than those for thermal beams.
Table 5 shows the dose ratios of Q cells relative to total 
tumor cell populations; these factors were used to compare the 
radiation doses necessary to obtain the net MN frequency of 
0.1 in Q cells with the doses required in the total tumor cell 
populations. All the values of the dose ratios were significantly 
larger than 1.0 (P < 0.05). Carbon-ion beam irradiation espe-
cially with a higher LET efficiently reduced the difference in 
γ-ray sensitivity between the total and Q tumor cell popula-
tions, especially in SAS/neo tumors, due to a greater recovery 
capacity in Q cells than in the total cell population at 9 h after 
HDRI and after RDRI. Reactor thermal and epithermal neu-
tron beam irradiation also efficiently reduced the difference in 
γ-ray sensitivity between the total and Q tumor cell popula-
tions following RDRI.
Discussion
PLD is the component of radiation damage that can be modi-
fied by post-irradiation conditions [24]. Under ordinary cir-
cumstances, PLD causes cell death. Changing cellular growth 
conditions or the microenvironment around cells influences the 
expression of PLD or PLDR, and thereby influences sensitivity 
to radiation. PLDR is favored by conditions that maintain cells 
without encouraging or allowing them to divide. Conditions 
found in solid tumors, regions of which may be far from blood 
vessels and low in glucose and oxygen, have a low extracel-
lular pH, and show high concentrations of cellular waste prod-
ucts, may prevent cells from proliferating and thereby promote 
the repair of PLD. Extensive studies on PLDR suggest that 
DNA double-stranded breaks (dsbs) are potentially lethal le-
sions that can be converted into lethal damage [5]. It was re-
ported that the conversion of potentially lethal lesions into le-
thal lesions might be a p53-dependent process and that PLDR 
was proportional to the percentage of radiation-induced DNA 
dsbs rejoined in 1 h in the cell lines with a normal p53 [25, 26].
Dose-rate is one of the principal factors determining the 
biologic consequences of a given absorbed dose. As the dose-
rate is lowered and the exposure time extended, the biologic 
effect of a given dose is generally reduced. The dose-rate ef-
fect, which is very important in radiotherapy, results from the 
repair of sublethal damage (SLD) that occurs during a long 
radiation exposure [24]. Incidentally, SLD repair is the opera-
Table 3.  Dose-Modifying Factors for SAS/mp53 Relative to SAS/neo Tumor Cellsa
High dose-rate immediately after High dose-rate 9 h after Reduced dose-rate
Surviving fraction = 0.03
  Total cells
    γ-rays (1.35 ± 0.1b) 1.15± 0.1 1.1 ± 0.1
    Carbon beams (18 keV/μm) (1.35 ± 0.1b) 1.1 ± 0.1 1.05 ± 0.1
    Carbon beams (50 keV/μm) (1.1 ± 0.1) 1.05 ± 0.1 1.0 ± 0.1
    Thermal beams 1.1 ± 0.1
    Epithermal beams 1.05 ± 0.1
aThe ratio of the physical radiation dose of external beams necessary to obtain each endpoint in SAS/mp53 tumor cells to that 
needed to obtain each endpoint in SAS/neo tumor cells. bMean ± standard error (n = 6).
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tional term for the increase in cell survival that is observed if 
a given radiation dose is split into two fractions separated by 
a time interval. Because continuous low dose-rate irradiation 
may be considered to be an infinite number of infinitely small 
fractions, the survival curve under these conditions also would 
be expected to have no shoulder and to be shallower than for 
a single acute exposure [24]. It was also reported that a nor-
mal functioning p53 gene is indispensable for a repair of DNA 
damage induced under low dose-rate irradiation [27, 28].
It is thought that decreasing the dose-rate reduces late 
effects in normal tissue much more than it decreases tumor 
control. Thus, the “therapeutic ratio” increases as the dose-rate 
decreases, because the therapeutic ratio is equal to the ratio 
of tumor control to normal tissue complications. Further, the 
Table 4.  Relative Biological Effectiveness for Carbon Beams Compared With γ-Raysa in Total and Quiescent Tumor Cells
LET values of carbon beams High dose-rate immediately after High dose-rate 9 h after Reduced dose-rate
SAS/neo
  Surviving fraction = 0.03
    Total cells
      18 keV/μm 1.35 ± 0.1b 1.5 ± 0.15 1.5 ± 0.15
      50 keV/μm 2.2 ± 0.2 2.6 ± 0.25 2.6 ± 0.25
      Thermal 3.2 ± 0.3
      Epithermal 3.7 ± 0.35
  Net micronucleus frequency = 0.1
    Total cells
      18 keV/μm 1.6 ± 0.15 1.7 ± 0.15 1.7 ± 0.15
      50 keV/μm 1.85 ± 0.2 2.45 ± 0.25 2.6 ± 0.25
      Thermal 4.2 ± 0.4
      Epithermal 4.7 ± 0.45
    Quiescent cells
      18 keV/μm 1.9 ± 0.2 2.4 ± 0.25 2.4 ± 0.25
      50 keV/μm 3.45 ± 0.35 4.2 ± 0.4 5.0 ± 0.5
      Thermal 6.4 ± 0.65
      Epithermal 7.3 ± 0.75
SAS/mp53
  Surviving fraction = 0.03
    Total cells
      18 keV/μm 1.6 ± 0.15b 1.6 ± 0.15 1.65 ± 0.15
      50 keV/μm 2.65 ± 0.25 2.65 ± 0.25 2.7 ± 0.25
      Thermal 3.1 ± 0.3
      Epithermal 3.3 ± 0.35
  Net micronucleus frequency = 0.1
    Total cells
      18 keV/μm 1.25 ± 0.1 1.2 ± 0.1 1.2 ± 0.1
      50 keV/μm 1.3 ± 0.15 1.35 ± 0.15 1.4 ± 0.15
      Thermal 2.3 ± 0.25
      Epithermal 2.45 ± 0.25
    Quiescent cells
      18 keV/μm 2.05 ± 0.2 2.4 ± 0.25 2.4 ± 0.25
      50 keV/μm 1.6 ± 0.15 1.75 ± 0.15 1.85 ± 0.2
      Thermal 3.8 ± 0.4
      Epithermal 4.2 ± 0.4
aRatio of radiation dose necessary to obtain each endpoint with γ-rays and radiation dose necessary to obtain each endpoint with carbon-ion beams. 
bMean ± standard error (n = 6).
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difference between early and late effects for low dose-rate ra-
diotherapy, as well as improving the therapeutic ratio, allows 
the delivery of a complete treatment in a short time, allowing 
the effects of tumor repopulation to be minimized. Namely, 
decreasing the dose-rate increases the therapeutic ratio, limited 
by tumor cell repopulation [24]. This is the primary rationale 
for low dose-rate radiotherapy. However, this rationale does 
not take into account the response of Q tumor cells. The cur-
rent study showed that lowering the dose-rate decreases the 
effect on Q cells more markedly than it reduces the effect on 
the total cell population (Table 2). Therefore, considering the 
Q cell response, it follows that the therapeutic ratio does not 
always increase when the dose-rate is reduced.
Following γ-ray irradiation, concerning whether PLDR 
after HDRI or the repair during RDRI, SAS/neo showed an 
apparent repair phenomenon in both total and Q cell popula-
tions (Fig. 1 and Table 2). Notably, Q cells in solid tumors 
with wild-type p53 exhibited greater capacities of the repair 
than the total cell population, probably due to the intratumor 
conditions, that is, hypoxic, nutrition-depleted, and low pH 
circumstances, where Q cells came into existence [10] (Fig. 1 
and Table 2). In contrast, no apparent repair was observed in 
total or Q cell populations within p53-mutated tumors (Fig. 1 
and Table 2).
Two major pathways for the repair of potentially lethal 
DNA dsbs exist in mammalian cells. The non-homologous 
end-joining (NHEJ) pathway is imprecise, error-prone, and 
mutagenic, and mutant cell lines lacking key components of 
this pathway all exhibit impaired kinetics of DNA dsb repair 
and exquisite radiosensitivity [29, 30]. Homologous recombi-
nation (HR) is a more precise (error-free) repair mechanism 
and is more important for the repair of dsbs in late-S and G2 
when a sister chromatid is available for the recombination re-
action. Cell lines with defects in HR also exhibit increased ra-
diosensitivity and decreased fidelity of repair [29, 31].
A cellular safeguard against genetic destabilization is acti-
vation of the p53 tumor suppressor protein, which commonly 
responds to DNA damage signals by inducing apoptosis or 
regulating the cell cycle including DNA damage repair [29, 
32]. As also shown in our previous report [33], the net MN 
frequencies in SAS/neo tumor cells were lower than those in 
SAS/mp53 tumor cells under all conditions (P < 0.05), prob-
ably resulting from exclusion of a higher number of radiation-
induced apoptotic SAS/neo cells than SAS/mp53 cells.
Loss-of-function of wild-type TP53 can result in loss of 
the G1/S cell-cycle checkpoint and an increase in HR [29, 32]. 
As p53 seems to interact with RAD51, the absence of normal 
p53 function is thought to enhance RAD51-mediated DNA 
pairing activity and HR, due to overexpression of RAD51 out 
of regulation by normal p53 [29, 32]. Thus, HR is thought to 
be a principal mechanism of DNA dsb repair in SAS/mp53 
cells. The very small repair capacity of SAS/mp53 cells in vivo 
may show that the repair in solid tumors with a mutant p53 is 
mainly due to, if anything, the NHEJ rather than HR.
After γ-ray irradiation, the dose ratios for SAS/mp53 cells 
relative to SAS/neo cells showed that SAS/mp53 tumor cells 
within solid tumors are less radiosensitive than SAS/neo tumor 
cells (Table 3). This is consistent with reports that tumor cells 
with a mutant p53 gene were more radioresistant than those 
with a wild-type p53 gene [33]. Since apparent repair phenom-
ena could be observed in solid tumors with a wild-type p53 
gene, the difference in sensitivity between SAS/neo and SAS/
mp53 was slightly reduced without significant differences af-
ter repair.
It is true that the RBE values can depend substantially on 
radiation quality like LET, radiation dose, the number of dose 
fractions, dose-rate, and biologic system or endpoint, includ-
ing the kind of irradiated cells, tumors, and tissues [34]. How-
ever, concerning the RBE values obtained in this study, as a 
whole, those of the carbon-ion beams and reactor thermal and 
epithermal neutron beams in Q cells were significantly larger 
than those in total cells irrespective of p53 status of tumor cells 
Table 5.  Dose-Modifying Factors for Quiescent Relative to Total Tumor Cellsa at Net Micronucleus Frequency 
of 0.1
High dose-rate immediately after High dose-rate 9 h after Reduced dose-rate
SAS/neo
  γ-rays (2.3 ± 0.25b) 2.35 ± 0.25 2.4 ± 0.25
  Carbon beams (18 keV/μm) (2.0 ± 0.2) 1.7 ± 0.15 1.65 ± 0.15
  Carbon beams (50 keV/μm) (1.9 ± 0.1) 1.75 ± 0.15 1.9 ± 0.2
  Thermal beams 1.2 ± 0.1
  Epithermal beams 1.1 ± 0.1
SAS/mp53
  γ-rays (2.0 ± 0.2b) 2.0 ± 0.2 2.0 ± 0.2
  Carbon beams (18 keV/μm) (1.25 ± 0.15) 1.3 ± 0.1 1.3 ± 0.15
  Carbon beams (50 keV/μm) (1.0 ± 0.1) 1.0 ± 0.1 1.0 ± 0.1
  Thermal beams 1.2 ± 0.1
  Epithermal beam 1.15 ± 0.1
aThe ratio of the dose of radiation necessary to obtain each endpoint in the quiescent cell population to that needed to obtain 
each endpoint in the total tumor cell population. bMean ± standard error (n = 6).
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(Table 4), reflecting the finding that Q cells showed signifi-
cantly and relatively lower sensitivity than did total cells under 
γ-ray irradiation and under carbon-ion beams or reactor neu-
tron beams, respectively. Nine hours was already shown to be 
long enough to repair the initial radiation-induced damage after 
γ-ray irradiation, and the capacity for PLDR was also shown 
to be greater in Q cells than in the total cell population [35]. 
In addition, the reduction in sensitivity caused by a decreas-
ing dose-rate under γ-ray irradiation, which has been ascribed 
to SLD repair during infinite split-dose irradiation and PLDR 
during RDRI [24], was also shown to be more marked than 
PLDR during 9 h after HDRI following γ-ray irradiation and 
more clearly observed in Q cells than in total cells within solid 
tumors [36]. Therefore, irrespective of p53 status of tumor 
cells, in both cell populations, the RBE values of carbon-ion 
beams became larger in the following order: immediately after 
HDR irradiation, 9 h after HDRI, and immediately after RDRI. 
Furthermore, not only in the total cells, but also in Q cells, 
because the sensitivity to carbon-ion beams became greater as 
the LET value increased (i.e., as the irradiated point became 
deeper in the SOBP of the carbon-ion beam; Fig. 1-3), the RBE 
values also became larger. This means precise treatment plan-
ning for targeting tumors is essential in clinics. Otherwise, se-
vere complications can be potentially caused in normal tissues 
around the target tumor. Concerning reactor neutron beams, 
the RBE values of the thermal neutron beams were higher than 
those of carbon-ion beams even with the higher LET value 
(50 keV/mm) and those of the epithermal beams showed sig-
nificantly greater values than the others (Table 4), irrespective 
of p53 status of tumor cells. This means that reactor neutron 
beams, especially epithermal beams, have as cytotoxic, or a 
more cytotoxic, effect on tumor cells as a whole, including the 
Q cell population than do accelerated carbon-ion beams with 
high LET values.
Carbon-ion beams, especially with high LET values, were 
shown to repress the repair by leaving the interval between 
γ-ray irradiation and the start of the assay or decreasing γ-ray 
irradiation dose-rate very efficiently in the total and Q cell 
populations (Table 2). The difference in radiosensitivity be-
tween the total and Q cell populations was markedly reduced 
with the use of carbon-ion beams, especially with high LET 
values (Table 5). Although our previous report demonstrated 
that the Q cell population has a much larger hypoxic fraction 
than the total cell population [11], the sensitivity to carbon-ion 
beams of the total cell population was similar to that of the Q 
cells. Thus, oxygenated and hypoxic cells in solid tumors have 
almost the same radiosensitivity to carbon-ion beams. The 
difference in sensitivity between the total and Q cell popula-
tions to γ-ray irradiation was more remarkable 9 h after HDRI 
than immediately after HDRI because of the more apparent 
observed PLDR in Q cells than in the total cells [11]. How-
ever, PLDR, especially by Q cells, after γ-ray irradiation was 
strongly suppressed with carbon-ion beams, especially high 
LET beams (Table 2), resulting in a marked reduction in the 
difference in sensitivity between the total and Q cells (Table 5). 
Moreover, the reduction in sensitivity caused by a decreasing 
dose-rate under γ-ray irradiation, which was more marked than 
PLDR during the 9 h after HDRI and more clearly observed 
in Q cells than in total cells [36], produced greater differences 
in sensitivity between the total and Q cells to γ-ray irradiation 
than 9 h after HDRI. Nevertheless, the decrease in sensitivity 
by a decreasing dose-rate was also efficiently inhibited with 
carbon-ion beams, especially those with high LET values. 
Concerning reactor neutron beams, both thermal and epither-
mal beams also inhibited the marked reduction in sensitivity of 
Q cells by a decreasing dose-rate, resulting in inducing a low 
difference in sensitivity between the total and Q cells, similar 
to that with carbon-ion beams with high LET values.
Because of the lower difference in radiation sensitivity 
among cell cycles and a lesser capacity for PLDR and SLD 
repair when carbon-ion beams, especially high LET beams, 
were used, the RBE values in Q tumor cells 9 h after HDRI 
and immediately after RDRI were relatively larger than those 
immediately after HDRI (Table 4), irrespective of p53 status 
of tumor cells. These radiobiologic advantages concerning 
the responses of intratumor Q cell populations provided us 
with another reliable rationale for high LET radiotherapy. The 
clinical trials revealed that carbon-ion radiotherapy provided 
definite local control and offered a survival advantage with-
out unacceptable morbidity in a variety of refractory tumors 
that include significantly more p53-mutated cells and/or hy-
poxic cells than normal tissues and that were hard to cure us-
ing conventional treatment modalities [18]. Additionally, only 
under RDRI reactor neutron beams could also cause almost 
similar radiosensitivity in Q cells to total cells. Taking this ra-
diobiologic characteristic into account, reactor neutron beams, 
especially epithermal beams, could also be a method of solid 
tumor treatment. However, difficulty certainly remains in ho-
mogeneous microdistribution of 10B atom in target tumors and 
sufficient physical dose deposition at a deep site uncondition-
ally necessary to cure and control deep-seated tumors, when 
the reactor neutron beams are used as a beam source for boron 
neutron capture therapy [17].
Solid tumors, especially human tumors, are thought to 
contain a high proportion of Q cells [10]. The presence of these 
cells is probably due, in part, to a microregional deficiency 
in the concentrations of oxygen, glucose, and other nutritional 
factors in the tumors caused by poor and heterogeneous tumor 
vascular supply [10]. This deficiency might promote MN for-
mation in Q tumor cells at 0 Gy (Table 1) [10, 37]. As shown 
here, Q cells have lower radiosensitivity than P cells in solid 
tumors in vivo, irrespective of the p53 status of tumor cells 
(Table 5) [33]. This means that more Q cells survive after ra-
diotherapy than P cells. Consequently, the control of Q cells 
also has a great impact on the outcome of radiotherapy. Thus, 
from the viewpoint of the tumor cell-killing effect including 
intratumor Q-cell control, a treatment modality for enhancing 
the Q-cell response has to be considered.
Conclusion
In terms of tumor cell-killing effect as a whole, including Q 
cells, accelerated carbon-ion beams, especially with greater 
LET values, are very useful for suppressing the dependency 
on the heterogeneity within solid tumors, as well as deposit-
ing the radiation dose precisely. For tumor control, including 
intratumor Q-cell control, accelerated carbon-ion beams, espe-
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cially with a higher LET, and reactor thermal and epithermal 
neutron beams were very useful for suppressing the recovery 
from radiation-induced damage irrespective of p53 status of 
tumor cells.
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